Collectively, our findings suggest that the oncogenic roles of MXD3 are concomitantly associated with deregulation of DBN1, RAB24, SLC34A1, PRELID1, LMAN2, F12, GRK6, RGS14, PRR7, and PFN3 in various cancer types. Here, SLC34A1 is linked to cancer.